[Hyperkalemia in heart failure: etiology, epidemiology and prognosis]

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Hyperkalemia (HK) frequently affects heart failure (HF) patients, often linked to comorbidities like chronic renal failure.
• Renin-angiotensin-aldosterone system inhibitors (RAASi) are crucial for HF treatment but can elevate serum potassium levels.
• HK necessitates RAASi dose reduction or discontinuation, negatively impacting HF patient prognosis.

Purpose of the Study:

• To evaluate the impact of novel potassium binders on managing hyperkalemia in heart failure patients.
• To assess the potential for new therapies to enable continued RAASi treatment in HF patients with hyperkalemia.

Main Methods:

• Review of pharmacological strategies for hyperkalemia treatment in outpatients.
• Analysis of the role of new potassium binders (patiromer, sodium zirconium cyclosilicate) in managing serum potassium levels.
• Assessment of the clinical implications of maintaining RAASi therapy in HF patients with hyperkalemia.

Main Results:

• Traditional hyperkalemia treatments have limited efficacy and adherence challenges.
• New potassium binders effectively reduce serum potassium levels.
• These binders facilitate the continuation of RAASi therapy, mitigating risks associated with hyperkalemia.

Conclusions:

• Novel potassium binders offer a promising strategy for managing hyperkalemia in heart failure patients.
• Effective hyperkalemia management with new binders allows for sustained RAASi therapy, potentially improving HF patient outcomes.
• This approach addresses a significant clinical challenge, enhancing the therapeutic benefit of RAASi in HF management.